Tech Company Financing Transactions

Leal Therapeutics Funding Round

On 8/17/2026, Leal Therapeutics raised $30 million in Series A funding from Alexandria Venture Investments, Dementia Discovery Fund and Eli Lilly and Company.

Transaction Overview

Company Name
Announced On
8/17/2026
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series A
Proceeds Purpose
The company intends to use the funds to advance LTX-001 through an initial readout of its Phase 1b/2a clinical trial in schizophrenia patients, as well as progress LTX-002 through additional dosing cohorts in an ongoing Phase 1/2 clinical trial in amyotrophic lateral sclerosis (ALS).

Company Information

Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Undisclosed
Worcester, MA Undisclosed
USA
Phone
Undisclosed
Email Address
Not Recorded
Overview
Developing novel therapeutics for patients with major disorders of the central nervous system.
Profile
Leal Therapeutics LinkedIn Company Profile
Social Media
Leal Therapeutics Company Twitter Account
Company News
Leal Therapeutics News
Facebook
Leal Therapeutics on Facebook
YouTube
Leal Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Asa Abeliovich
  Asa Abeliovich LinkedIn Profile  Asa Abeliovich Twitter Account  Asa Abeliovich News  Asa Abeliovich on Facebook


 

 

Browse more venture capital transactions:

Prev: 8/17/2026: Higgsfield AI venture capital transaction
Next: 8/17/2026: Terra Industries venture capital transaction

 

Share this article

 


About Database of VC Transactions

We do our best to record every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary